2026-04-27T21:53:42Zhttps://uvadoc.uva.es/oai/requestoai:uvadoc.uva.es:10324/693102024-07-30T19:01:42Zcom_10324_40357com_10324_952com_10324_894col_10324_40358
Reduction in the risk of peripheral neuropathy and lower decrease in kidney function with metformin, linagliptin or their fixed-dose combination compared to placebo in prediabetes: a randomized controlled trial
Gabriel, Rafael
Boukichou Abdelkader, Nisa
Gilis-Januszewska, Aleksandra
Makrilakis, Konstantinos
Gómez Huelgas, Ricardo
Kamenov, Zdravko
Paulweber, Bernhard
Satman, Ilhan
Djordjevic, Predrag
Alkandari, Abdullah
Mitrakou, Asimina
Lalic, Nebojsa
Egido, Jesús
Más Fontao, Sebastián
Calvet, Jean Henri
Pastor Jimeno, José Carlos
Lindström, Jaana
Lind, Marcus
Acosta, Tania
Silva, Luis
Tuomilehto, Jaakko
Diabetes - Diagnosis
Diabetes - Prevention
Diabetes - Prevención
Diabetes - Treatment
Diabetes - Tratamiento
Nervous system - Diseases
Nervioso, Sistema - Enfermedades
Sistema nervioso periférico - Enfermedades
Neuropatia
Neurology
Kidneys - Diseases
Riñones - Enfermedades
Pharmacology
Drugs
Medicamentos
Lifestyle
Calidad de vida
Clinical trials
Ensayos clínicos
Public health
Producción Científica
Objective: To compare the effect of glucose-lowering drugs on peripheral nerve and kidney function in prediabetes. Methods: Multicenter, randomized, placebo-controlled trial in 658 adults with prediabetes treated for 1 year with metformin, linagliptin, their combination or placebo. Endpoints are small fiber peripheral neuropathy (SFPN) risk estimated by foot electrochemical skin conductance (FESC < 70 μSiemens) and estimated glomerular filtration rate (eGFR). Results: Compared to the placebo, the proportion of SFPN was reduced by 25.1% (95% CI:16.3–33.9) with metformin alone, by 17.3% (95% CI 7.4–27.2) with linagliptin alone, and by 19.5% (95% CI 10.1–29.0) with the combination linagliptin/metformin (p < 0.0001 for all comparisons). eGFR remained +3.3 mL/min (95% CI: 0.38–6.22) higher with the combination linagliptin/metformin than with the placebo (p = 0.03). Fasting plasma glucose (FPG) decreased more with metformin monotherapy −0.3 mmol/L (95%CI: −0.48; 0.12, p = 0.0009) and with the combination metformin/linagliptin −0.2 mmol/L (95% CI: −0.37; −0.03) than with the placebo (p = 0.0219). Body weight (BW) decreased by −2.0 kg (95% CI: −5.65; −1.65, p = 0.0006) with metformin monotherapy, and by −1.9 kg (95% CI: −3.02; −0.97) with the combination metformin/linagliptin as compared to the placebo (p = 0.0002). Conclusions: in people with prediabetes, a 1 year treatment with metformin and linagliptin, combined or in monotherapy, was associated with a lower risk of SFPN, and with a lower decrease in eGFR, than treatment with placebo.
2024-07-30T10:53:01Z
2024-07-30T10:53:01Z
2023
info:eu-repo/semantics/article
Journal of Clinical Medicine, 2023, Vol. 12, Nº. 5, 2035
2077-0383
https://uvadoc.uva.es/handle/10324/69310
10.3390/jcm12052035
2035
5
Journal of Clinical Medicine
12
2077-0383
eng
https://www.mdpi.com/2077-0383/12/5/2035
info:eu-repo/semantics/openAccess
http://creativecommons.org/licenses/by/4.0/
© 2023 The authors
Atribución 4.0 Internacional
MDPI
SI